{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.214","value":"0.03"},{"groupId":"OG001","spread":"0.163","value":"-0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.221","value":"0.03"},{"groupId":"OG001","spread":"0.259","value":"-0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.196","value":"0.04"},{"groupId":"OG001","spread":"0.192","value":"-0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.210","value":"0.02"},{"groupId":"OG001","spread":"0.243","value":"-0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.230","value":"0.05"},{"groupId":"OG001","spread":"0.186","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.234","value":"0.07"},{"groupId":"OG001","spread":"0.225","value":"-0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.228","value":"0.07"},{"groupId":"OG001","spread":"0.166","value":"-0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.187","value":"0.07"},{"groupId":"OG001","spread":"0.158","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.250","value":"0.07"},{"groupId":"OG001","spread":"0.140","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.299","value":"0.07"},{"groupId":"OG001","spread":"0.110","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.268","value":"0.08"},{"groupId":"OG001","spread":"0.222","value":"-0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.272","value":"0.07"},{"groupId":"OG001","spread":"0.164","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.299","value":"0.06"},{"groupId":"OG001","spread":"0.182","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Cycle 27 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.261","value":"0.05"},{"groupId":"OG001","spread":"0.159","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 30 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.282","value":"0.00"},{"groupId":"OG001","spread":"0.186","value":"0.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 33 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.231","value":"0.06"},{"groupId":"OG001","spread":"0.216","value":"0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 36 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.255","value":"0.06"},{"groupId":"OG001","spread":"0.214","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 39 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"The EQ-5D-5L is a descriptive classification consisting of five dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort. The five-level version (no problems, slight problems, moderate problems, severe problems, and extreme problems) uses a 5-point Likert scale, with 1 being no problems and 5 being extreme problems.","dispersionType":"Standard Deviation","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"MEAN","populationDescription":"FAS. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)","title":"Change From Baseline in EQ-5D-5L","type":"SECONDARY","unitOfMeasure":"scores on a scale"}